Biomedicine hub最新文献

{"title":"Pleuroperitoneal Leak: A Rare Complication of Peritoneal Dialysis.","authors":"Maria Lafrid, Narjiss Labioui, Mohammed Massine El Hammoumi, Mohammed Hallak, Hajar Laasli, Abdelali Bahadi, El Hassane Kabiri, Driss Elkabbaj","doi":"10.1159/000545281","DOIUrl":"https://doi.org/10.1159/000545281","url":null,"abstract":"<p><strong>Introduction: </strong>Pleuroperitoneal leakage is a rare but dramatical cause of pleural effusion; it can lead to the cessation of peritoneal dialysis. It typically manifests as respiratory distress and reduced drainage volumes.</p><p><strong>Case presentation: </strong>In this article, we report a case of pleuroperitoneal leak in a patient undergoing continuous ambulatory peritoneal dialysis who presented to the emergency with shortness of breath, lower limb edema, and weight gain. The diagnosis was established through pleural puncture, revealing that the pleural fluid is transudative with elevated glucose level which is pathognomonic for this condition, \"sweet hydrothorax.\" Furthermore, the composition of this fluid was almost identical to the peritoneal dialysis effluent. The management of this case involved temporarily discontinuing peritoneal dialysis and performing pleurodesis. The evolution was favorable, and peritoneal dialysis was resumed 2 weeks later.</p><p><strong>Conclusion: </strong>Patients on peritoneal dialysis who present with significant pleural effusion, especially if it is unilateral, should prompt clinicians to consider the possibility of a pleuroperitoneal leak.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"93-97"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Slowly Progressive Type 1 Diabetes following Steroid-Sensitive Relapsing Nephrotic Syndrome in Childhood: A Case Report.","authors":"Masashi Kitahara, Kenji Kurata","doi":"10.1159/000545216","DOIUrl":"https://doi.org/10.1159/000545216","url":null,"abstract":"<p><strong>Introduction: </strong>In rare cases, idiopathic nephrotic syndrome (NS) and type 1 diabetes coexist, with diabetes typically preceding NS or presenting almost simultaneously with an acute onset requiring immediate insulin therapy.</p><p><strong>Case presentation: </strong>We report a unique case of a 5.1-year-old male who developed idiopathic NS and experienced glycosuria during steroid treatments for relapses, initially attributed to steroid-induced hyperglycemia. At age 10.2, he developed persistent glycosuria without steroid administration, and an oral glucose tolerance test confirmed diabetes. Despite positive anti-insulinoma-associated protein-2 antibodies, the patient maintained non-insulin-dependent glycemic control until, 13 months later, rapid-onset hyperglycemia necessitated insulin therapy, leading to a diagnosis of slowly progressive type 1 diabetes (SPT1D).</p><p><strong>Conclusion: </strong>This case represents the first reported instance of steroid-sensitive relapsing NS followed by SPT1D in childhood.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"81-85"},"PeriodicalIF":0.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coincidence of Takayasu Arteritis and Multiple Sclerosis: Narrative Review and Case Report.","authors":"Andrea Wesser, Andreas Albert Braun","doi":"10.1159/000545237","DOIUrl":"https://doi.org/10.1159/000545237","url":null,"abstract":"<p><strong>Introduction: </strong>Takayasu arteritis (TA) and multiple sclerosis (MS) are both immune-mediated diseases that can coexist, with TA causing vascular inflammation and MS involving demyelination driven by aberrant T-cell activity. The overlap of these conditions highlights shared immune mechanisms, such as T-cell dysregulation and cytokine release, underscoring the need for a nuanced understanding of their interplay, which is explored in a narrative review of reported cases.</p><p><strong>Case presentation: </strong>We narrate all reported cases of TA in patients with MS and report the case of a 57-year-old woman with MS with suspected bilateral optic neuritis and typical contrast-medium enhancement in both optic nerves. Because of normal visual acuity on both eyes, malignant hypertension, and fundoscopic findings indicative of hypertensive retinopathy, we diagnosed hypertensive retinopathy with secondary contrast-medium enhancement of the optic nerves. We established antihypertensive medication and searched for secondary causes of hypertension and highly elevated erythrocyte sedimentation rate, which led to the finding of large vessel wall inflammation and the diagnosis of TA.</p><p><strong>Conclusion: </strong>TA can present with a variety of ocular symptoms, including hypertensive retinopathy, retinal ischemia, and anterior ischemic optic neuropathy, often mimicking other diseases. While rare, the coexistence of TA and MS, including cases associated with interferon-beta therapy, suggests shared immune mechanisms and underscores the need for careful monitoring of patients with MS receiving immunomodulatory treatments. The broad spectrum of potential causes for optic nerve abnormalities necessitates a thorough evaluation to avoid misdiagnosis and ensure appropriate treatment.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"72-80"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12028982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Characteristics Are Associated with Appointment \"No-Show\" at a Tertiary Academic Glaucoma Service: A Cross-Sectional Study.","authors":"Samantha Rosen, Julie Cassidy, Hai-Wei Liang, Lauren M Wasser, Doowon Huh, Andrew M Williams","doi":"10.1159/000545307","DOIUrl":"https://doi.org/10.1159/000545307","url":null,"abstract":"<p><strong>Introduction: </strong>Appointment \"no-shows\" (NS) are a significant issue for glaucoma patients, potentially leading to loss to follow-up, disease progression, and irreversible vision loss. This study investigates sociodemographic and clinical risk factors associated with NS at a tertiary academic eye center.</p><p><strong>Methods: </strong>A retrospective review of 100 glaucoma patients at the University of Pittsburgh Medical Center (UPMC) Vision Institute over 1 year was conducted. Patients were categorized as NS if they missed any glaucoma service appointment and as never no-show (NNS) if no appointments were missed. Baseline demographic, medical, and ophthalmic data were collected. Socioeconomic disadvantage was measured using the area deprivation index (ADI) based on residential ZIP codes.</p><p><strong>Results: </strong>Of 100 patients, 35 were classified as NS and 65 as NNS. NS patients had significantly higher ADI scores (79 vs. 65; <i>p</i> = 0.03) and were more frequently Black (54% [19/35] vs. 26% [17/65]; <i>p</i> = 0.01). Medical comorbidities were more common in NS patients (83% [29/35] vs. 48% [31/65]; <i>p</i> < 0.001), as were mental health diagnoses (34% [12/35] vs. 8% [5/65]; <i>p</i> < 0.001). Insurance type, glaucoma type, intraocular pressure, and visual acuity were not significantly different between groups.</p><p><strong>Conclusion: </strong>Higher socioeconomic disadvantage, Black race, medical comorbidities, and mental health diagnoses were associated with appointment NS among glaucoma patients. These findings highlight the need for targeted interventions to address these risk factors, improve follow-up adherence, and reduce the risk of disease progression.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"86-92"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Ophthalmic Medications on Conjunctival Goblet Cell Density in New Zealand White Rabbits.","authors":"Sarahi Del Carmen Gómez Macías, Ricardo Osvaldo Jauregui Franco, José María Torres-Arellano, Elba Yadira Correa Gallegos, José Manuel Medina Espinosa, Alejandra Sánchez Ríos, Oscar Olvera Montaño","doi":"10.1159/000544102","DOIUrl":"10.1159/000544102","url":null,"abstract":"<p><strong>Introduction: </strong>The conjunctiva contains numerous specialized cells called conjunctival goblet cells (CGCs). The topical application of specific eye drops to the ocular surface has conclusively been linked to cause a reduction in CGCs, a condition which has been associated with dry eye and other ocular surface disorders. The purpose of this study was to assess if the use of benzalkonium chloride (BAK) as a preservative in common ophthalmic medications affects CGCs' density in New Zealand white (NZW) rabbit conjunctivas.</p><p><strong>Methods: </strong>Data from seven preclinical studies conducted between March 2016 and April 2021 were analyzed, involving 146 male NZW rabbits aged 2 to 3 months. Prior to study participation, rabbits underwent a 7-day quarantine period in individual housing, during which their general health was monitored. Rabbits had ad libitum access to water and food, with intake data recorded. Comprehensive ophthalmological examinations were performed on all eyes prior to and throughout the studies. The density of corneal endothelial cells was specifically assessed using AB/PAS staining and quantified with a high-power (40X) field objective (ocular 18 × 22), expressed as a percentage relative to epithelial cells.</p><p><strong>Results: </strong>No statistically significant differences were found between the with-BAK group and without-BAK group. The mean density in the 30-day group presented a statistically significant higher density than the >30-day group (<i>p</i> = 0.005). Analysis of the treatment revealed that antibiotic/steroid combination group had a higher average number of CGCs compared to both the antihistaminic group (<i>p</i> = 0.004) and hypotensive agent group (<i>p</i> = 0.047).</p><p><strong>Conclusion: </strong>Exposure to BAK-preserved medications for 30 days results in a higher density of CGCs compared to prolonged exposure to BAK-preserved medications exceeding 30 days. The pharmacological effects and associated cellular damage induced by BAK vary depending on the specific medication with which it is combined.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"64-71"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Calciphylaxis: A Case Report.","authors":"Maria Lafrid, Narjiss Labioui, Mohamed Hallak, Abdelaali Bahadi, Driss El Kabbaj, Mohamed Allaoui, Yassir Zajjari","doi":"10.1159/000543604","DOIUrl":"10.1159/000543604","url":null,"abstract":"<p><strong>Introduction: </strong>Calciphylaxis is a rare and severe disorder characterized by obstructive small vessel disease in the subcutaneous adipose tissue and skin, leading to necrotic skin lesions. The condition poses a significant risk of mortality due to infectious and ischemic complications.</p><p><strong>Case presentation: </strong>We present the case of a 60-year-old woman, with a history of renal lithiasis, hypertension, and end-stage renal disease on hemodialysis complicated by hyperparathyroidism and aortic valve replacement. She developed extensive necrotic lesions on both lower limbs and upper extremities, prompting a diagnosis of calciphylaxis. Radiographic and biopsy findings supported the diagnosis, revealing characteristic calcifications. Treatment involved antibiotics, oral thiosulfate, daily hemodialysis, hyperbaric oxygen therapy, and discontinuation of calcium and alfacalcidol, with alendronate initiation. Unfortunately, despite these interventions, the patient experienced a rapid clinical decline, developing septic shock necessitating bilateral leg amputations. Regrettably, she succumbed to the disease 10 days later.</p><p><strong>Conclusion: </strong>This case underscores the challenging prognosis of calciphylaxis and the need for effective therapeutic options, including surgical intervention and access to injectable thiosulfate.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"44-49"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroimaging-Based Responses to Blood Pressure Augmentation in Acute Ischaemic Stroke: A Systematic Review.","authors":"Rudy Goh, Shaddy El-Masri, Daniel Zweck, Dominic Spicer, Felix Ng, Stephen Bacchi, Jim Jannes, Timothy Kleinig","doi":"10.1159/000543341","DOIUrl":"10.1159/000543341","url":null,"abstract":"<p><strong>Introduction: </strong>In acute ischaemic stroke, the key treatment to reduce infarct growth is reperfusion, achieved through thrombolysis, endovascular thrombectomy, or endogenous reperfusion. Prior to definitive reperfusion therapy, blood pressure augmentation may enhance cerebral perfusion and reduce interim infarct growth. This study aimed to summarise the existing evidence from randomised controlled trials on the use of imaging for patient selection and the assessment of blood pressure augmentation in acute ischaemic stroke.</p><p><strong>Methods: </strong>A systematic review was conducted of the databases PubMed, Embase, and Cochrane Library in accordance with the PRISMA guidelines. The systematic review was prospectively registered on PROSPERO.</p><p><strong>Results: </strong>Initial searches returned 266 results, of which 4 fulfilled inclusion criteria. Most identified studies did not utilise imaging for patient selection and the assessment of blood pressure augmentation in ischaemic stroke. Only two studies utilised magnetic resonance imaging and/or magnetic resonance perfusion imaging for patient selection, while one study used non-contrast CT brain. No studies utilised CT perfusion imaging for patient selection or outcome assessment post-blood pressure augmentation. There is also a lack of evidence regarding the association between specific perfusion imaging parameters, such as cerebral blood volume and delay time, and clinical outcomes post-blood pressure augmentation.</p><p><strong>Conclusion: </strong>Imaging is a potentially valuable surrogate marker of cerebral perfusion, yet it has not been routinely used for patient selection and assessment in blood pressure augmentation in acute ischaemic stroke trials. Additional research is required to determine its utility in assessing the efficacy of blood pressure augmentation in ischaemic stroke.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"50-56"},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Tacrolimus Ointment Alone in the Treatment of Pediatric Vitiligo: A Systematic Review and Meta-Analysis.","authors":"Alshaymaa Abdulrahman Alshaikh, Joud Abdulrahman Alshaikh, Hind Alatawi","doi":"10.1159/000543311","DOIUrl":"10.1159/000543311","url":null,"abstract":"<p><strong>Introduction: </strong>Vitiligo, a skin disorder affecting melanocytes, poses treatment challenges. There is a need to investigate the role of tacrolimus in pediatric cases for its efficacy and safety. The present study aimed to assess the safety and efficacy of tacrolimus ointment in treating pediatric vitiligo patients.</p><p><strong>Methods: </strong>A review study was conducted, and a literature search was done on 2 August 2023, by using the words \"vitiligo\" and \"tacrolimus\" through five databases including PubMed. We found 8 studies from 930 records.</p><p><strong>Results: </strong>The rates of excellent, moderate, mild, minimal improvement, and no response were 29% (95% CI: 16-47), 26% (95% CI: 19-35), 28% (95% CI: 20-37), 19% (95% CI: 12-29), and 8% (95% CI: 2-25). No systemic side effects were reported. The overall prevalence of local side effects was 14% (95% CI: 7-24). Burning sensation prevalence was 11% (95% CI: 7-18), while pruritus prevalence was 9% (95% CI: 2-33). Study limitations encompassed varied vitiligo sites, patient demographics, and follow-up durations, lacked comparative treatment data, and necessitated further research on combined therapies, especially in pediatric cases.</p><p><strong>Conclusion: </strong>Tacrolimus showed good efficacy regarding the re-pigmentation improvement in pediatric vitiligo patients. Furthermore, no systemic side effects were reported and local side effects were minimal mainly in the form of a burning sensation and pruritus.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"33-43"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodistribution of Polymeric Nanoparticles following in utero Delivery to a Nonhuman Primate.","authors":"David A Eaton, Anna Y Lynn, Juliana M Surprenant, Emily I Deschenes, Mary Elizabeth Guerra, Rachel Rivero, Nicholas K Yung, Merissa O'Connor, Peter M Glazer, Mert Ozan Bahtiyar, W Mark Saltzman, David H Stitelman","doi":"10.1159/000543138","DOIUrl":"10.1159/000543138","url":null,"abstract":"<p><strong>Introduction: </strong>Monogenic diseases can be diagnosed before birth. Systemic fetal administration of nanoparticles (NPs) grants therapeutic access to developing stem cell populations impacted by these classes of disease. Delivery of editing reagents in these NPs administered before birth has yielded encouraging results in preclinical mouse models of monogenic diseases.</p><p><strong>Methods: </strong>To translate this strategy clinically, the safety and efficacy of this strategy in larger animals will be necessary. We performed a pilot biodistribution study in 3 fetal nonhuman primates (NHPs) in mid-gestation examining systemic delivery of polymeric NPs loaded with fluorescent dye.</p><p><strong>Results: </strong>We found several similarities in distribution to our experience in mice, namely, extensive uptake in fetal liver and spleen. A striking finding that is not recapitulated in the mouse was the accumulation of NPs in the zones of proliferation and ossification of the fetal bone. Of great importance, there did not appear to be NP accumulation in the fetal male or female germline zones or maternal tissue.</p><p><strong>Conclusion: </strong>These studies were vital to the next step of testing editing reagents in the fetal NHP with a goal of treating monogenic diseases before birth.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"23-32"},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meconium Influences Pulmonary Short-Chain Fatty Acid Concentration in Porcine Meconium Aspiration Model.","authors":"Harry Ramcharran, Auyon Ghosh, Qinghe Meng, Guanqun Li, Evan Skakel Chernov, Mark Lutz, Heidi M Mansour, Joshua Satalin, Sarah Satalin, Donald P Gaver, Jason H T Bates, Gary Nieman, Michaela Kollisch-Singule","doi":"10.1159/000542807","DOIUrl":"10.1159/000542807","url":null,"abstract":"<p><strong>Introduction: </strong>The factors influencing meconium aspiration syndrome (MAS) severity remain poorly understood. In a piglet model of MAS, we hypothesized the respiratory microbiome would reflect the bacterial signature of meconium with short-chain fatty acid (SCFA) accumulation as a byproduct of bacterial fermentation.</p><p><strong>Methods: </strong>Cesarean section at approximately 115-day term was performed on two sows. Male (9) and female (3) piglets were delivered, instrumented, anesthetized, and randomized into a Control (<i>n</i> = 6) or MAS group (<i>n</i> = 6). MAS received a meconium slurry (3 mL/kg) aspiration injury. Experimental animals were monitored continuously, ventilated, and resuscitated for 24 h. BALF was collected for 16S microbiome sequencing and SCFA analysis by gas chromatography. Effects of SCFAs on A549 alveolar pulmonary epithelial in vitro cell viability and inflammation were assessed.</p><p><strong>Results: </strong>The MAS group had significantly higher fluid and vasopressor requirements than the Control group (<i>p</i> < 0.05) though both groups developed lung injury. The meconium microbiome demonstrated a difference in genus proportions as compared with the BALF of the Control and MAS groups. The MAS group had a relative increase in propionic acid-forming bacteria and higher BALF concentrations of propionic acid (0.6 ± 0.2 mmol/kg) than the Control group (0.2 ± 0.2 mmol/kg; <i>p</i> > 0.05). Propionic acid was associated with decreased pulmonary epithelial cell viability and an upregulated pro-inflammatory response.</p><p><strong>Conclusions: </strong>Meconium may host a microbiome with byproducts that interact with the pulmonary epithelium and influence lung injury severity in MAS.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"8-22"},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}